ClinicalTrials.gg
RecruitingNCT07334119Updated May 20, 2026

Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors

A Phase 1 interventional study of MT-304 and MT-304 + Nivolumab in HER2-Expressing Solid Tumors, sponsored by Myeloid Therapeutics. Recruiting at 7 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-20.

Sponsored by Myeloid Therapeutics · Phase 1, Interventional, and Treatment

How we know · 14 judgments

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies testing nivolumab in Carcinoma, Transitional Cell — 4 open to participants now, 9 under way, 1 of them phase 3. Nivolumab · Carcinoma, Transitional Cell.

Planned enrollment
4th of 16
60 · median 35
Started
2025
the only one that year
Phase 1
4 of 16
none open now
Registered
16th of 16
by date

Among the 16 studies testing nivolumab in Carcinoma, Transitional Cell, this one is the 4th largest by planned enrollment, is the only one that started in 2025, is one of 4 in phase 1, and was the 16th registered.

Carcinoma, Transitional Cell

633 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.

Browse Carcinoma, Transitional Cell studies →

Open to participants now

4 of the 16 studies testing nivolumab in Carcinoma, Transitional Cell are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 149 Carcinoma, Transitional Cell studies recruiting now, 123 (83%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing nivolumab in Carcinoma, Transitional Cell, or all of them as a file.
02

Study summary

This clinical trial is designed to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of MT-304 in adults with advanced HER2-expressing solid tumors. The main questions it aims to answer are:

  • What is the safety profile of MT-304 when administered alone or with nivolumab?
  • What is the recommended Phase 2 dose (RP2D) of MT-304?

Participants will:

  • Receive MT-304 alone (every 14 days) or with nivolumab (every 28 days).
  • Attend regular clinic visits for assessments and monitoring.
  • Continue treatment until disease progression, unacceptable toxicity, or study discontinuation.
Read the detailed description

This multicenter, open-label, Phase 1 trial is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of MT-304 in adults aged 18 and older with advanced HER2-expressing solid tumors.

The study consists of two treatment modules:

  • Module 1 (Monotherapy): Participants receive MT-304 every 14 days for 28-day cycles, with dosing adjustments based on clinical benefit and safety evaluations.
  • Module 2 (Combination Therapy): Participants receive MT-304 in combination with nivolumab, administered every 14 days and 28 days, respectively, also allowing for dosing adjustments.

The Bayesian Optimal Interval (BOIN) design will guide dose escalation, overseen by a Safety Review Committee to establish the recommended Phase 2 dose (RP2D).

Regular assessments, including vital signs and laboratory tests, will monitor safety and efficacy throughout the trial, with follow-up visits for up to 2 years post-treatment.

03

Conditions studied

  • HER2-Expressing Solid Tumors

Keywords

  • Anti-HER2 chimeric antigen receptor
  • Chimeric Antigen Receptor (CAR)
  • mRNA
  • Lipid nanoparticle (LNP)
  • Urothelial carcinoma
  • Endometrial carcinoma
  • Ovarian epithelial carcinoma
  • Breast carcinoma (all subtypes)
  • Gastric adenocarcinoma
  • Esophageal adenocarcinoma
  • Non-small cell lung cancer
  • Colorectal carcinoma
  • Biliary cancer (including Gallbladder carcinoma and extrahepatic cholangiocarcinoma)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 years or above
  • confirmed diagnosis of or advanced epithelial cancer expressing (Note: Participants with other tumor types expressing HER2 may be considered pending discussion with the Medical Monitor).
  • per 1.1 criteria.
  • (ECOG) performance status Grade of 0 or 1.
  • Adequate Organ function

Exclusion criteria

Exclusion Criteria:

  • Known active and/or carcinomatous meningitis.
  • Any acute illness including fever.
  • History of symptomatic congestive heart failure
  • History of (noninfectious) pneumonitis/interstitial lung disease that required or has current pneumonitis/interstitial lung disease.
  • Uncontrolled pleural effusion, pericardial effusion, or ascites
  • Active disease not related to prior therapy for primary that has required systemic therapy in the last 1 year.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    MT-304 Monotherapy

    Participants receive MT-304 administered intravenously once every 14 days (Q14D) in escalating dose levels.

    Drug: MT-304

  • Experimental
    MT-304 + Nivolumab Combination Therapy

    Participants receive MT-304 administered intravenously once every 14 days (Q14D) in combination with nivolumab as "per local label" administered once every 28 days (Q28D).

    Drug: MT-304 + Nivolumab

Interventions

  • DrugMT-304

    Safety, tolerability, and pharmacokinetics will be evaluated.

    Also known as: mRNA-LNP

  • DrugMT-304 + Nivolumab

    Drug page: NivolumabStudies of NivolumabNivolumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Combination therapy begins after monotherapy dose clearance by the Safety Review Committee.

    Also known as: mRNA-LNP

06

What researchers measure

Primary outcomes

  1. Type, incidence and severity of Adverse Events

    Safety and tolerability profile assessed by the Common Terminology Criteria for Adverse Events v5.

    Time frame: Up to 90 days from the last dose of Investigational Medicinal Product (IMP)

  2. Number of Participants With Change From Baseline in Vital Signs (Composite Safety Outcome)

    Body temperature, body weight, pulse rate, and blood pressure (systolic and diastolic) assessed collectively; participants with clinically significant changes in any vital sign parameter will be summarized as a composite safety outcome.

    Time frame: Up to 30 days from the last dose of IMP

  3. Number of Participants With Abnormal Clinical Laboratory Parameters (Composite Safety Outcome)

    Hematology, clinical chemistry, coagulation, virology testing, and urinalysis assessed collectively; participants with abnormalities in any laboratory parameter will be summarized as a composite safety outcome.

    Time frame: Up to 30 days from the last dose of IMP

  4. Number of Participants With Change From Baseline in ECG Parameters (Composite Safety Outcome)

    PR interval, QRS duration, QT interval, corrected QT interval (QTc), and heart rate assessed collectively from 12-lead ECG recordings; participants with clinically significant changes in any ECG parameter will be summarized as a composite safety outcome.

    Time frame: Screening through Day 28, with assessments performed on Screening, Day 1 (pre-dose), and Day 28.

  5. Maximum Tolerated Dose (MTD)

    The MTD in Module 1 (monotherapy) will be determined based on dose-limiting toxicities (DLTs).

    Time frame: 28 days from the last dose of IMP

  6. Optimal Biological Dose (OBD)

    The OBD in Module 2 (combination) will be identified based on dose-limiting toxicities (DLTs).

    Time frame: 28 days from the last dose of IMP

Secondary outcomes

  1. Pharmacokinetics (PK)

    PK Parameter: Maximum plasma concentration (Cmax)

    Time frame: From Day 1, Day 2, Day 8, and Day 15 of Cycles 1 and 2, and Day 1 of Cycle 3 (each cycle is 28 days).

  2. Pharmacokinetics (PK)

    PK parameter: Area under Curve

    Time frame: From Day 1, Day 2, Day 8, and Day 15 of Cycles 1 and 2, and Day 1 of Cycle 3 (each cycle is 28 days).

  3. Pharmacokinetics (PK)

    PK parameter: Time of maximum observed plasma concentration (tmax)

    Time frame: From Day 1, Day 2, Day 8, and Day 15 of Cycles 1 and 2, and Day 1 of Cycle 3 (each cycle is 28 days).

  4. Pharmacokinetics (PK)

    PK parameter:Terminal half-life (t½)

    Time frame: From Day 1, Day 2, Day 8, and Day 15 of Cycles 1 and 2, and Day 1 of Cycle 3 (each cycle is 28 days).

  5. Pharmacokinetics (PK)

    PK parameter: Plasma Clearance (CL)

    Time frame: From Day 1, Day 2, Day 8, and Day 15 of Cycles 1 and 2, and Day 1 of Cycle 3 (each cycle is 28 days).

  6. Pharmacokinetics (PK)

    PK parameter: Volume of Distribution (Vd)

    Time frame: From Day 1, Day 2, Day 8, and Day 15 of Cycles 1 and 2, and Day 1 of Cycle 3 (each cycle is 28 days).

  7. Pharmacokinetics (PK)

    PK parameter: Mean residence time (MRT)

    Time frame: From Day 1, Day 2, Day 8, and Day 15 of Cycles 1 and 2, and Day 1 of Cycle 3 (each cycle is 28 days).

  8. To assess adverse events of special interest (AESI) by measuring infusion reaction

    Time frame: Upto 90 days from the last dose of IMP

  9. To assess adverse events of special interest (AESI) by measuring cytokine release syndrome (CRS)

    Time frame: Upto 90 days from the last dose of IMP

  10. To assess adverse events of special interest (AESI) by measuring immune effector cell-associated neurotoxicity syndrome (ICANS)

    Time frame: Upto 90 days from the last dose of IMP

  11. To assess adverse events of special interest (AESI) by measuring hypersensitivity reaction

    Time frame: Upto 90 days from the last dose of IMP

  12. To assess the incidence of second primary malignancies reported as adverse events of special interest (AESI) occurring during the study treatment period and long-term follow-up.

    Time frame: From first dose of Investigational Medicinal Product (IMP) through end of study and follow-up (up to 2 years)

07

Study locations

7 of 7 sites recruiting
  • The Kinghorn Cancer Centre
    Darlinghurst, New South Wales 2010, Australia
    Recruiting
    • Dr Rasha Cosman · Contact+61393555655
    • Dr Rasha Cosman · Principal investigator
  • Scientia Clinical Research Ltd
    Randwick, New South Wales 2031, Australia
    Recruiting
  • Calvary Mater Newcastle
    Waratah, New South Wales 2298, Australia
    Recruiting
    • Kerrie Cornall · Contact+61240143282
    • Dr Jordan Cohen · Principal investigator
  • Icon Cancer Centre South Brisbane
    South Brisbane, Queensland 4101, Australia
    Recruiting
    • A/Prof Jermaine Coward · Contact+61737374500
    • A/Prof Jermaine Coward · Principal investigator
  • Cancer Research SA Pty Ltd
    Adelaide, South Australia 5000, Australia
    Recruiting
    • Dr Meena Okera · Contact+61883592565
    • Dr Meena Okera · Principal investigator
  • Cabrini Health
    Melbourne, Victoria 3144, Australia
    Recruiting
    • Dr. Prachi Bhave · Contact+61395083437
    • Dr. Prachi Bhave · Principal investigator
  • Linear Clinical Research
    Nedlands, Western Australia 6009, Australia
    Recruiting
    • Dr Timothy Humphries · Contact+61863825100
    • Dr Timothy Humphries · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Jan 2027, 14 months after the start.

Of 62 industry-sponsored phase 1 interventional studies under Carcinoma, Transitional Cell, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 57. This study's planned 14 months is below that.

Counting every sponsor, half of 99 studies reached it within 45 months; a quarter within 31 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2025
First posted
Jan 12, 2026
StartActual
Nov 25, 2025
Primary completionEst.
Jan 31, 2027
CompletionEst.
Mar 30, 2028
Last update
May 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07334119
Lead sponsor
Myeloid Therapeutics
Collaborators
CREATE Medicines
Responsible party
Sponsor
First posted
Jan 12, 2026
Start date
Nov 25, 2025
Primary completion
Jan 31, 2027 (estimated)
Completion
Mar 30, 2028 (estimated)
Last update
May 20, 2026

Study contacts

Project Manager
Contact
MTX-HER2-304_ClinicalStudy@novotech-cro.com
+61731376255
Clinical Department
Contact
mt-304.clinical@createmedicines.com
+16174651022
Matthew Maurer, MD
study director · Myeloid Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion